Upload
cassie
View
63
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2 Trial. Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting. Disclosure. - PowerPoint PPT Presentation
Citation preview
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2 Trial
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
Disclosure
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
Outline Slide
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
Background
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
Primary Objective
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
Secondary Objectives
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
Design
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
Final OPTIMIZE-2 study design
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
Demographics, Baseline Characteristics
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
SRE Rate (Primary Endpoint)
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
Time-to-First SRE
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
Skeletal Morbidity Rate (SMR)
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
Safety Summary
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
Bone Markers Change from Baseline
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
Conclusions
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
Back Ups
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
Number of Infusions Prior to Study
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
Renal Adverse Events
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting